AR059693A2 - Una composicion farmaceutica de micofenolato y su uso - Google Patents

Una composicion farmaceutica de micofenolato y su uso

Info

Publication number
AR059693A2
AR059693A2 ARP070100839A ARP070100839A AR059693A2 AR 059693 A2 AR059693 A2 AR 059693A2 AR P070100839 A ARP070100839 A AR P070100839A AR P070100839 A ARP070100839 A AR P070100839A AR 059693 A2 AR059693 A2 AR 059693A2
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
mycophenolate
prevention
treatment
halograft
Prior art date
Application number
ARP070100839A
Other languages
English (en)
Inventor
Jacky Vonderscher
Barbara Haeberlin
Mak Ching Pong
Armin Meinzer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26309105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR059693(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9607564.3A external-priority patent/GB9607564D0/en
Priority claimed from GBGB9622028.0A external-priority patent/GB9622028D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR059693A2 publication Critical patent/AR059693A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composicion farmacéutica, que comprende una sal de micofenolato farmacéuticamente aceptable, con revestimiento entérico. El uso de una composicion farmacéutica, para la preparacion de un medicamento para inmunosupresion, particularmente para la prevencion o el tratamiento de rechazo de trasplante de haloinjerto o xenoinjerto, nativo o transgénico de organo, tejido o de células, o enfermedad e injerto contra huésped para el tratamiento o prevencion de enfermedades mediadas por el sistema inmune y/o enfermedades inflamatorias.
ARP070100839A 1996-04-12 2007-03-01 Una composicion farmaceutica de micofenolato y su uso AR059693A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9607564.3A GB9607564D0 (en) 1996-04-12 1996-04-12 Organic compounds
GBGB9622028.0A GB9622028D0 (en) 1996-10-24 1996-10-24 Organic compounds

Publications (1)

Publication Number Publication Date
AR059693A2 true AR059693A2 (es) 2008-04-23

Family

ID=26309105

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP970101419A AR006583A1 (es) 1996-04-12 1997-04-10 Una composición farmacéutica
ARP070100839A AR059693A2 (es) 1996-04-12 2007-03-01 Una composicion farmaceutica de micofenolato y su uso

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP970101419A AR006583A1 (es) 1996-04-12 1997-04-10 Una composición farmacéutica

Country Status (34)

Country Link
US (3) US6025391A (es)
EP (2) EP0892640B1 (es)
JP (2) JP3779732B2 (es)
CN (1) CN1104238C (es)
AR (2) AR006583A1 (es)
AT (2) ATE259228T1 (es)
AU (1) AU725388B2 (es)
BE (1) BE1010963A3 (es)
BR (1) BR9708624A (es)
CO (1) CO4900024A1 (es)
CY (1) CY2243B1 (es)
CZ (1) CZ291811B6 (es)
DE (4) DE19781690D2 (es)
DK (1) DK0892640T3 (es)
ES (2) ES2178510B1 (es)
FR (1) FR2747920B1 (es)
GB (1) GB2326339B (es)
GR (1) GR1002893B (es)
HK (2) HK1051484A1 (es)
HU (1) HU224919B1 (es)
ID (1) ID18663A (es)
IE (1) IE970267A1 (es)
IL (1) IL126431A (es)
IT (1) IT1297045B1 (es)
LU (1) LU91094I2 (es)
MY (1) MY119049A (es)
NL (1) NL300157I2 (es)
NO (2) NO322891B1 (es)
NZ (1) NZ332117A (es)
PT (1) PT892640E (es)
RU (2) RU2203659C2 (es)
TR (1) TR199802056T2 (es)
TW (1) TW457098B (es)
WO (1) WO1997038689A2 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE474590T1 (de) 1999-05-10 2010-08-15 Paolo Brenner Kombination von immunsuppressiven substanzen zur behandlung oder vorbeugung von transplantat abstossungen
US20030050692A1 (en) * 2000-12-22 2003-03-13 Avantec Vascular Corporation Delivery of therapeutic capable agents
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
MY145753A (en) * 2001-10-19 2012-03-30 Isotechnika Inc Novel cyclosporin analog formulations
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
GB0314553D0 (en) * 2003-06-21 2003-07-30 Weatherford Lamb Electric submersible pumps
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
BRPI0509148B8 (pt) * 2004-03-22 2021-05-25 Abbott Products Gmbh composições farmacêuticas orais de produtos contendo lipase, em particular de pancreatina contendo tensoativos, seus usos e respectivos processos de fabricação
EP1740564A2 (en) * 2004-04-26 2007-01-10 Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság Process for preparation of mycophenolic acid and ester derivatives thereof
WO2005105771A1 (en) 2004-04-27 2005-11-10 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
DE602005020014D1 (de) * 2004-07-20 2010-04-29 Teva Gyogyszergyar Zartkoeruen Kristallines mycophenolat-natrium
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
US20060235009A1 (en) * 2005-02-08 2006-10-19 Richard Glickman Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors
WO2006086500A2 (en) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Compositions and methods for treating vascular, autoimmune and inflammatory diseases
JP5140586B2 (ja) 2005-07-29 2013-02-06 アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング 滅菌パンクレアチン粉末の製法
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
CN1985994B (zh) * 2005-12-19 2011-01-12 康泰乐(北京)医药科技发展有限公司 改进的包含霉酚酸盐的包有肠溶衣的药物组合物
WO2007093346A1 (en) * 2006-02-13 2007-08-23 Novartis Ag High dosage of mycophenolic acid (mpa)
JP2007230948A (ja) * 2006-03-02 2007-09-13 Univ Meijo 腸溶性化硬カプセル
US10072256B2 (en) * 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
US20080009050A1 (en) * 2006-06-29 2008-01-10 Zdenek Pokluda Regulation of acid metabolite production
US20080182998A1 (en) * 2007-01-25 2008-07-31 Apotex Fermentation Inc. Novel crystalline mycophenolate sodium polymorph and processes to manufacture same
US20080176937A1 (en) * 2007-01-23 2008-07-24 Apotex Fermentation Inc. Novel crystalline mycophenolate sodium polymorph and processes to manufacture same
TW200904982A (en) * 2007-04-11 2009-02-01 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Method for reducing impurity level in mycophenolic acid fermentation
KR20100063059A (ko) * 2007-08-13 2010-06-10 파나세아 바이오테크 리미티드 마이폴틱 장용정을 함유하는 서방출형 조성물 및 이의 조제방법
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
CA2729834A1 (en) * 2008-07-09 2010-01-14 Aspreva International Ltd. Formulations for treating eye disorders
US20110086102A1 (en) * 2009-10-13 2011-04-14 Teva Pharmaceutical Industries Ltd. Delayed release compositions
EA201270544A1 (ru) * 2009-10-13 2012-09-28 Тева Фармасьютикал Индастриз Лтд. Композиции с отсроченным высвобождением
WO2011051967A2 (en) * 2009-10-23 2011-05-05 Alkem Laboratories Ltd Pharmaceutical compositions comprising mycophenolate and processes for preparing thereof
CN103880799A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
CN103880800A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
GB201100786D0 (en) 2011-01-18 2011-03-02 Ems Sa Pharmaceutical compositions of immunosuppressants
WO2013041205A1 (de) 2011-09-19 2013-03-28 Pyxirion Pharma Gmbh Neue therapeutische konzepte zur behandlung von gefässerkrankungen
RS57497B1 (sr) 2013-03-14 2018-10-31 Alkermes Pharma Ireland Ltd Prolekovi fumarata i njihova upotreba u lečenju raznih bolesti
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
WO2014167442A1 (en) 2013-03-26 2014-10-16 Wockhardt Limited Pharmaceutical compositions comprising mycophenolic acid or salts thereof
AU2015204192B2 (en) * 2014-01-06 2020-03-26 Shield TX (UK) Limited Dosage regimen of ferric trimaltol
AU2015218587B2 (en) 2014-02-24 2017-04-27 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
GB201418710D0 (en) 2014-10-21 2014-12-03 Iron Therapeutics Holdings Ag Dosage regimen
US10213411B2 (en) 2015-08-27 2019-02-26 Vijaykumar Rajasekhar Use of prodrugs of fumarates in treating heart failure diseases
US10463642B2 (en) 2016-02-01 2019-11-05 Vijaykumar Rajasekhar Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate
WO2018170022A2 (en) * 2017-03-13 2018-09-20 Okava Pharmaceuticals, Inc. Methods and compositions for delivering mycophenolic acid active agents to non-human mammals
JP2024508327A (ja) 2021-03-03 2024-02-26 サナ バイオテクノロジー，インコーポレイテッド 心筋細胞療法と併用する免疫抑制療法、及び関連する方法ならびに組成物
CN114028334B (zh) * 2021-12-10 2023-08-29 卓和药业集团股份有限公司 一种肺部给药的免疫抑制剂的制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1157099A (en) * 1966-09-27 1969-07-02 Ici Ltd Fermentation Process
GB1157100A (en) * 1966-09-27 1969-07-02 Ici Ltd Pharmaceutical Compositions
GB1173942A (en) * 1967-06-06 1969-12-10 Bellon Labor Sa Roger New 2,3-Dihydro-1,4-Benzoxazines
GB1158387A (en) * 1967-06-13 1969-07-16 Ici Ltd Procedure for Isolation of Mycophenolic Acid
GB1203328A (en) * 1968-06-04 1970-08-26 Ici Ltd Pharmaceutical compositions
GB1261060A (en) * 1969-09-09 1972-01-19 Ici Ltd Phthalen-1-one derivatives
US3705946A (en) * 1971-05-25 1972-12-12 Lilly Co Eli Method of treating hyperuricemia
JPS5542995B2 (es) * 1972-02-24 1980-11-04
US3825571A (en) * 1971-07-31 1974-07-23 Chugai Pharmaceutical Co Ltd Mycophenolic acid derivatives
US3868454A (en) * 1972-08-14 1975-02-25 Lilly Co Eli Psoriasis treatment with mycophenolic acid derivatives
US3777020A (en) * 1972-08-14 1973-12-04 Lilly Co Eli Psoriasis treatment with mycophenolic acid
US4005108A (en) * 1973-04-03 1977-01-25 Research Corporation Novel anti-leukemic diterpenoid triepoxides
US3880995A (en) * 1973-05-14 1975-04-29 Lilly Co Eli Treatment of arthritis with mycophenolic acid and derivatives
US3903071A (en) * 1973-05-22 1975-09-02 Lilly Co Eli Mycophenolic acid derivatives
JPS517116A (en) * 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
US4234684A (en) * 1979-12-11 1980-11-18 Eli Lilly And Company Method of preparing mycophenolic acid glucoside
IT1150194B (it) * 1982-02-23 1986-12-10 Chiesi Farma Spa Formulazioni farmaceutiche ad attivita'antiinfiammatoria, analgesica,antipiretica e gastroprotettiva
US4680299A (en) * 1984-04-30 1987-07-14 E.I. Du Pont De Nemours And Company 2-phenyl-4-quinolinecarboxylic acids and pharmaceutical compositions thereof
US4686234A (en) * 1985-11-27 1987-08-11 Syntex (U.S.A) Inc. Mycophenolic acid derivatives in the treatment of inflammatory diseases, in particular rheumatoid arthritis
US4959387A (en) * 1986-01-23 1990-09-25 Syntex (U.S.A.) Inc. Mycophenolic acid derivatives in the treatment of rheumatoid arthritis
US4725622A (en) * 1986-01-23 1988-02-16 Syntex (U.S.A.) Inc. Mycophenolic acid derivatives in the treatment of rheumatoid arthritis
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
US4727069A (en) * 1987-01-30 1988-02-23 Syntex (U.S.A.) Inc. Heterocyclic aminoalkyl esters of mycophenolic acid, derivatives thereof and pharmaceutical compositions
US4847381A (en) * 1987-08-31 1989-07-11 American Cyanamid Company 2-Phenyl-4-quinoline carboxylic acids
US5135934A (en) * 1990-07-06 1992-08-04 Du Pont Merck Pharmaceutical Company 3-phenyl-5,6-dihydrobenz(c) acridine-7-carboxylic acids and related compounds as immunosuppressive agents
US5372298A (en) * 1992-01-07 1994-12-13 The Regents Of The University Of California Transient liquid phase ceramic bonding
CA2086642C (en) * 1992-01-09 2004-06-15 Randall E. Morris Method of treating hyperproliferative vascular disease
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
WO1994026265A1 (en) * 1993-05-06 1994-11-24 Pharmagenesis, Inc. 16-hydroxytriptolide composition and method for immunotherapy
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
US5428040A (en) * 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
JP3844491B2 (ja) * 1993-10-01 2006-11-15 シンテックス（ユー・エス・エイ）インコーポレイテッド ミコフェノール酸モフェチル高用量経口用懸濁剤
WO1995013082A1 (en) * 1993-11-08 1995-05-18 Pharmagenesis, Inc. Immunotherapy composition and method
JP4105761B2 (ja) * 1993-11-19 2008-06-25 アボット・ラボラトリーズ ラパミシン（マクロライド）の半合成類似体免疫調節剤

Also Published As

Publication number Publication date
NO2007004I2 (no) 2009-10-19
CN1215991A (zh) 1999-05-05
CZ291811B6 (cs) 2003-06-18
NL300157I2 (nl) 2004-12-01
WO1997038689A2 (en) 1997-10-23
DK0892640T3 (da) 2004-05-10
LU91094I2 (fr) 2004-10-11
IT1297045B1 (it) 1999-08-03
DE122004000038I1 (de) 2006-01-26
ES2178510A1 (es) 2002-12-16
ES2178510B1 (es) 2004-08-16
CN1104238C (zh) 2003-04-02
CZ326798A3 (cs) 1999-01-13
US6025391A (en) 2000-02-15
DE19781690D2 (de) 1999-04-08
DE69727559T2 (de) 2004-12-16
EP0892640B1 (en) 2004-02-11
FR2747920A1 (fr) 1997-10-31
TR199802056T2 (xx) 1999-02-22
GB2326339A (en) 1998-12-23
NL300157I1 (nl) 2004-10-01
JP2006063086A (ja) 2006-03-09
GB9821304D0 (en) 1998-11-25
ID18663A (id) 1998-04-30
AT408415B (de) 2001-11-26
RU2615397C2 (ru) 2017-04-04
MY119049A (en) 2005-03-31
EP0892640A2 (en) 1999-01-27
HUP9903373A2 (hu) 2001-04-28
NO2007004I1 (no) 2007-04-16
NO322891B1 (no) 2006-12-18
CY2243B1 (en) 2003-07-04
ATE259228T1 (de) 2004-02-15
NO984728L (no) 1998-12-02
NO984728D0 (no) 1998-10-09
US6172107B1 (en) 2001-01-09
IL126431A0 (en) 1999-08-17
TW457098B (en) 2001-10-01
DE122004000038I2 (de) 2006-04-27
HK1016490A1 (en) 1999-11-05
DE69727559D1 (de) 2004-03-18
AU2384397A (en) 1997-11-07
IL126431A (en) 2005-03-20
IE970267A1 (en) 1997-10-22
CO4900024A1 (es) 2000-03-27
ATA905997A (de) 2001-04-15
US6306900B1 (en) 2001-10-23
GR1002893B (el) 1998-04-10
BR9708624A (pt) 1999-08-03
EP1221316A1 (en) 2002-07-10
JP2000503665A (ja) 2000-03-28
HK1051484A1 (zh) 2003-08-08
ES2216141T3 (es) 2004-10-16
PT892640E (pt) 2004-06-30
JP3779732B2 (ja) 2006-05-31
WO1997038689A3 (en) 1997-12-04
HUP9903373A3 (en) 2001-05-28
NZ332117A (en) 2000-04-28
RU2203659C2 (ru) 2003-05-10
HU224919B1 (en) 2006-04-28
FR2747920B1 (fr) 1999-12-31
GB2326339B (en) 2000-04-19
BE1010963A3 (fr) 1999-03-02
AU725388B2 (en) 2000-10-12
ITRM970207A1 (it) 1998-10-11
AR006583A1 (es) 1999-09-08

Similar Documents

Publication Publication Date Title
AR059693A2 (es) Una composicion farmaceutica de micofenolato y su uso
LTC1131065I2 (lt) Dialkilfumaratai, skirti autoimuninėms ligoms gydyti
ES2062392T3 (es) Medicamentos que comprenden salmeterol y fluticasona.
WO1995028957A3 (en) Methods for inducing t cell tolerance to a tissue or organ graft
DK209088A (da) Medicinpraeparater, deres fremstilling og anvendelse
ES2070492T3 (es) Reactividad inmunitaria para oncogenes expresados activos para diagnostico y tratamiento de estados malignos.
CA2093513A1 (en) Methods and compositions for suppressing allograft rejection in mammals
ES2141065T1 (es) Preparacion de vacunas subunitarias contra el virus sincitial respiratorio.
IL112667A0 (en) 6-substituted derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them
AU7814498A (en) Multivalent (in ovo) avian vaccine
HUP0104410A2 (hu) Ateroszklerózis megelőzésére és/vagy kezelésére szolgáló gyógyszerkészítmények
BR9612821A (pt) Métodos para a prevenção de rejeição de enxerto em transplante e para a produção de uma célula de hospedeiro para terapia genética universal
WO2002020619A3 (en) HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3)
HK1045456A1 (en) Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
DK0821593T3 (da) Konjugat af et aktivt middel, et protein og eventuelt et for kroppen ikke som fremmed anset nativt protein
ES2046246T3 (es) Composicion terapeutica para combatir el sida.
FI924215A (fi) Anvaendningen av il-4 foer oekning av immunreaktionen foerorsakad infektiosa antigen aemnen
CO5180574A1 (es) Micofenolato mofetil en asociacion con peg-inf-a
FI883247A (fi) 7-/1h-pyrrool-3-yl/-substituerade 3,5-dihydroxihept-6-ensyror, 7-/1h-pyrrol-3-yl/-susbtituerade 3,5 -dihydroxiheptansyror, motsvarande -laktoner och salter av dem, foerfarande foer framstaellning av dessa, deras anvaendning som laekemedel, farmaceutiska preparat och mellanprodukter.
Wennberg et al. Efficacy of immunosuppressive drugs in islet xenotransplantation: A study in the pig‐to‐rat model
IT1270958B (it) Composizioni farmaceutiche a base di nimesulide, somministrabili per via orale, non gastrolesive e/o a rilascio controllato
Arons et al. The use of unburned skin from burned animals as homografts with the adjunctive use of convalescent burn serum
Raj et al. Immunomodulation of excretory secretory materials from the filarial parasite Setaria digitata
Carlisle Intestinal anaphylaxis to ovalbumin
Sivan TEXT SELECTIONS

Legal Events

Date Code Title Description
FC Refusal